Replies to post #76082 on PharmaCyte Biotech Inc (PMCB)

[DragonBear]

Janssen, nor anyone else-wrong

for that matter would be interested in PharmaCyte's CiaB therapy if that was true.

There have been no collaborative agreements with Jannsen (or anyone else) announced.

You can't show not one single targeted therapy having superior intellectual property to CiaB

CIAB has not shown any superiority to any pancreatic cancer treatment currently undergoing FDA trials. There have been no approved FDA clinical trials with CIAB. There's no FDA trial data generated by CIAB. Where's the IND?

Neither have there been any clinical studies with an alkylating agent such as Ifosfamide, having been used alone as a Metronomic therapy for metastatic Pancreatic cancer. That is why a Jansen and "anyone else" isn't interested.